Amaros Closes Series A, Expands Board to Launch AI Ophthalmic Platform

Amaros Inc., a Silicon Valley-based startup specializing in ophthalmic intelligence, recently announced the successful close of its Series A financing round. The funding, backed by both new and existing mission-aligned investors, marks a significant milestone in the company's journey to revolutionize eye care by transforming fragmented clinical data into actionable insights. Vartan Ghazarossian, Ph.D., co-founder and CEO of Amaros, emphasized the importance of leveraging data in ophthalmology, noting that critical information often remains siloed, hindering advancements in the field. "Too much critical information remains siloed—limiting how we study, diagnose, and treat eye diseases," Ghazarossian stated. "With our AI-powered EvidenceEngine, we're building the industry's first dynamic real-world intelligence platform, empowering physicians, researchers, and companies to transform unstructured data into life-changing insights." The Series A funding will be instrumental in several aspects of Amaros' growth and impact. It will finance continued product development, expand commercial partnerships, and aid in the global scaling of the company's engineering, clinical, and data science teams. This influx of capital is crucial for accelerating the commercialization of the EvidenceEngine platform, which is designed to integrate diverse datasets, including electronic medical records, imaging, genomics, provider notes, and claims, into structured information that offers real-time insights. In addition to the financial boost, Amaros has formed a distinguished advisory board comprising global leaders in eye care, artificial intelligence, and clinical trial design. These experts will guide the commercialization process and shape the platform's applications across various ophthalmic innovations. Notable members include: David S. Boyer, M.D.: Renowned retinal specialist and senior partner at Retina-Vitreous Associates Medical Group in Los Angeles, with extensive experience as a lead investigator for age-related macular degeneration and diabetic retinopathy trials. David Eichenbaum, M.D.: Partner and director of research at Retina Vitreous Associates of Florida, known for his expertise in retina-focused pharmaceutical development and clinical trial execution. Peter K. Kaiser, M.D.: Chaney Family Endowed Chair in Ophthalmology Research at Cole Eye Institute, Cleveland Clinic, and professor of ophthalmology at Case Western Reserve School of Medicine, recognized for his excellence in retinal imaging and clinical trial design. T. Y. Alvin Liu, M.D.: Endowed professor in AI at the Wilmer Eye Institute, Johns Hopkins University, and inaugural director of the James P. Gills Jr., M.D., and Heather Gills Artificial Intelligence Innovation Center, the first dedicated, endowed AI center at the JHU School of Medicine. Sumit P. Shah, M.D.: Partner at NJ Retina, Prism Vision Group, and clinical associate professor at Rutgers Robert Wood Johnson Medical School, with a strong background in retina-focused clinical trials. Michael A. Singer, M.D.: Clinical professor at UT Health Science Center and director of clinical research at Medical Center Ophthalmology Associates in San Antonio, Texas, a key opinion leader in real-world data and imaging biomarkers. Vance Thompson, M.D.: Founder of Vance Thompson Vision and a pioneer in refractive and cataract surgery, known for his contributions to anterior-segment innovation and clinical trial leadership. Ben Toker, co-founder and president of Amaros, expressed enthusiasm about the advisory board's potential impact. "Our advisory board brings together visionary leaders with deep expertise in clinical excellence, real-world evidence, and business innovation," Toker said. "Their insights will be pivotal as we transform fragmented and siloed data into precision intelligence—advancing clinical research, enhancing care delivery, and driving smarter commercialization. With their partnership, we are accelerating the adoption of ophthalmic AI and building the unified ecosystem that modern eye care demands." The EvidenceEngine platform is a powerful tool that integrates and analyzes a wide array of ophthalmic data sources to provide timely and actionable insights. By doing so, it aims to optimize clinical trials, identify unmet patient needs, and refine treatment strategies. The platform's human-centric design ensures that it is user-friendly and accessible to all stakeholders involved in eye care, from healthcare providers to pharmaceutical companies. One of the platform's key features is its ability to handle and interpret complex data types, such as genomics and imaging, alongside more traditional data sources like medical records and provider notes. This holistic approach allows for a more comprehensive understanding of eye health conditions and can significantly enhance diagnostic and therapeutic processes. For instance, by consolidating and analyzing large amounts of imaging data, the EvidenceEngine can help detect early signs of age-related macular degeneration and diabetic retinopathy, enabling timely interventions that can improve patient outcomes. Moreover, the platform's real-time capabilities are particularly valuable in the fast-moving landscape of clinical research. It enables researchers to access up-to-date information, streamlining the process of hypothesis testing and data-driven decision-making. For healthcare providers, the platform offers personalized treatment recommendations based on the latest evidence, potentially leading to more effective and efficient patient care. Industry insiders have praised Amaros' efforts to bridge the gap between data fragmentation and actionable intelligence. Dr. David S. Boyer, one of the advisory board members, highlighted the platform's potential to redefine clinical practice. "Amaros' EvidenceEngine has the capability to transform the way we approach eye care by providing us with invaluable insights and tools that can enhance our diagnostic and treatment capabilities," he said. Dr. Peter K. Kaiser, another advisory board member, echoed similar sentiments, emphasizing the platform's role in advancing clinical research. "The integration of AI and real-world data in ophthalmology is long overdue, and Amaros is leading the charge," Kaiser stated. "The EvidenceEngine platform will accelerate the pace of innovation and help bring new treatments to patients more quickly." Amaros was founded in 2019 with the vision of harnessing AI to improve ophthalmic care. The company's flagship platform, EvidenceEngine, represents a significant step forward in achieving this goal. Designed to address the challenges of data fragmentation, the platform promises to deliver precision intelligence that can drive better outcomes for patients and stakeholders alike. Contacts: For media inquiries, please contact: media@launchlabpartners.com In summary, Amaros Inc.'s successful Series A funding and the formation of a distinguished advisory board represent significant milestones in the company's mission to transform ophthalmic care through AI. The EvidenceEngine platform's ability to integrate and analyze diverse data sources in real-time is poised to enhance clinical research, improve diagnosis and treatment, and drive innovation in the eye care industry. Industry leaders see great potential in the platform, validating its importance and impact in the field.